AstraZeneca vaccine review is in the 'final stages,' Health Canada says - Action News
Home WebMail Sunday, November 10, 2024, 04:29 PM | Calgary | 4.0°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Politics

AstraZeneca vaccine review is in the 'final stages,' Health Canada says

Dr. Supriya Sharma, chief medical adviser at Health Canada, says the department is poised to make a decision on whether to authorize a promising COVID-19 vaccine from AstraZeneca in the coming days.

Health Canada has received all the necessary scientific data but questions for the company remain

An employee in personal protective equipment (PPE) removes vials of AstraZeneca's COVISHIELD coronavirus disease (COVID-19) vaccine from a visual inspection machine inside a lab at Serum Institute of India, in Pune, India, on November 30, 2020. (Francis Mascarenhas/Reuters)

Health Canada's chief medical adviser said todaythe department is poised to make a decision on whether to authorize a promising COVID-19 vaccine from AstraZeneca in the coming days.

Dr. Supriya Sharma told the House of Commons health committee that the regulator has received all the necessary scientific information from the company but is still looking into questions aboutlabelling and the product monograph the information disseminated by Health Canada to medical professionalsabout how and when a vaccine should be administered and in what groups.

Thedepartmenthas said for weeks its decision on the product would be released soon.

"That review is ongoing. It is in the final stages and the length of time that that takes is really dependenton a number of factors," Sharma said, adding the regulator has put some questions to AstraZeneca and is awaiting responses.

Other countries notably Australia, the European Union and the United Kingdom alreadyhave authorized the product for use in their jurisdictions, but under differentconditions.

In Australia, for example, the product was approved but regulators there recommended a three-month wait between shots because data suggestthe product's efficacy rate improves with a longer interval. The European Medicines Agency recommendeda dose interval of between four and 12 weeks.

(CBC News)

"It's complicated. We know that we've got different regulators looking at the same data for AstraZeneca and are making different decisions based on the science. That's why this is taking a little bit longer than the ones we've done before," Sharma said.

"We're going back and forth with the company," she said, adding discussions on the "terms and conditions" of the product are still ongoing.

The United Stateshas not yet approved the shot for the American marketplace.

Health Canada and the U.S. Food and Drug Administration (FDA) approved the Pfizer and Moderna products within days of one another last December.

Unlike those two shots, which are based on mRNA technlogy, the AstraZeneca uses a more conventional viral vector load vaccine technology.

The company has faced questions about its decentralized manufacturing process the product will be made at different sites worldwide, sometimes by third parties its stage three clinical trials and the product'seffectiveness against emerging variants.

Some jurisdictions,notably France, have restricted the vaccine to people under the age of 65 despite the World Health Organization's insistence that the product is safe and effectivefor all age groups.

Add some good to your morning and evening.

Your daily guide to the coronavirus outbreak. Get the latest news, tips on prevention and your coronavirus questions answered every evening.

...

The next issue of the Coronavirus Brief will soon be in your inbox.

Discover all CBC newsletters in theSubscription Centre.opens new window

This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply.